

Hikma launches Cisplatin Injection

29 July 2019 | News

Today one in every six injectable generic medicines used in US hospitals is a Hikma product



Hikma Pharmaceuticals PLC the multinational pharmaceutical company, has launched Cisplatin Injection, 1mg/mL in 50mL and 100mL vials, in the United States through its US affiliate, Hikma Pharmaceuticals USA Inc.

Cisplatin Injection is indicated as therapy to be employed as follows:

- **Metastatic Testicular Tumors**

In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures.

- **Metastatic Ovarian Tumors**

In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin Injection and cyclophosphamide. Cisplatin Injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin Injection therapy.

- **Advanced Bladder Cancer**

Cisplatin Injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.

According to IQVIA, US sales of Cisplatin Injection, 1mg/mL in 50mL and 100mL, were approximately \$5 million in the 12

months ending May 2019.